NCT00543062View on ClinicalTrials.gov

Staccato Prochlorperazine Thorough QT/QTc

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Cardiotoxicity
Interventions
DRUG

Inhaled placebo

Inhaled Staccato placebo (0 mg)

DRUG

Oral placebo

Oral placebo (identical to 400 mg moxifloxacin)

DRUG

Inhaled prochlorperazine 5 mg

Staccato prochlorperazine 5 mg, single dose

DRUG

Inhaled prochlorperazine 10 mg

Inhaled prochlorperazine 10 mg, single dose

DRUG

Oral moxifloxacin

Oral moxifloxacin 400 mg, si/ngle dose

Trial Locations (1)

47714

Covance Clinical Research Unit Inc., Evansville

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY

NCT00543062 - Staccato Prochlorperazine Thorough QT/QTc | Biotech Hunter | Biotech Hunter